| |
| |
|
| Insider
Information: |
Weiss Michael S |
| Relationship: |
Director |
| City: |
Berkeley Heights |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
16,329,233 |
|
|
Indirect Shares
|
14,546,388 |
|
|
| Direct
Value |
$213,572,850 |
|
|
|
Indirect Value
|
$235,490,819 |
|
|
| Total
Shares |
30,875,621 |
|
|
| Total
Value |
$449,063,669 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
 -2.8%
|
-135.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
10% Owner |
2010-05-10 |
1,320,418 |
2003-11-21 |
0 |
Premium* |
|
|
Genta Inc De |
GNTAQ |
Director |
2005-08-05 |
537,238 |
2004-07-14 |
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
Director |
2008-08-22 |
25,000 |
|
0 |
Premium* |
|
|
TG Therapeutics Inc |
TGTX |
CEO |
2024-01-06 |
13,074,929 |
2020-06-22 |
14,434,214 |
Premium* |
|
|
Fortress Biotech, Inc. |
FBIO |
See Remarks, Director,... |
2024-01-01 |
1,346,985 |
2013-12-19 |
0 |
Premium* |
|
|
Checkpoint Therapeutics, Inc. |
CKPT |
Director |
2017-06-15 |
0 |
2024-05-14 |
112,174 |
Premium* |
|
|
Avenue Therapeutics, Inc. |
ATXI |
Director |
2018-08-07 |
24,663 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
126 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2009-02-03 |
5 |
S |
$2.70 |
$69,428 |
D/D |
(25,714) |
1,887,986 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2009-12-07 |
5 |
S |
$3.30 |
$544,500 |
D/D |
(165,000) |
1,722,986 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2009-12-16 |
5 |
A |
$0.00 |
$0 |
D/D |
335,281 |
2,058,267 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-05 |
4 |
S |
$3.58 |
$1,038,558 |
D/D |
(290,100) |
1,768,167 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-05 |
4 |
OE |
$1.30 |
$260,000 |
D/D |
200,000 |
1,968,167 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-12 |
4 |
OE |
$1.30 |
$195,000 |
D/D |
150,000 |
1,968,167 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-12 |
4 |
S |
$4.12 |
$618,000 |
D/D |
(150,000) |
1,818,167 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-13 |
4 |
S |
$4.80 |
$96,480 |
D/D |
(20,100) |
1,948,067 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-23 |
4 |
S |
$4.41 |
$377,893 |
D/D |
(85,690) |
1,862,377 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-29 |
4 |
S |
$4.63 |
$667,831 |
D/D |
(144,240) |
1,718,137 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-04-30 |
4 |
S |
$5.53 |
$569,590 |
D/D |
(103,000) |
1,615,137 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-05-03 |
4 |
S |
$6.16 |
$924,000 |
D/D |
(150,000) |
1,465,137 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-05-06 |
4 |
S |
$5.59 |
$262,730 |
D/D |
(47,000) |
1,418,137 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-05-09 |
4 |
S |
$6.09 |
$304,500 |
D/D |
(50,000) |
1,368,137 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
10% Owner |
– – • |
2010-05-10 |
4 |
S |
$5.94 |
$283,451 |
D/D |
(47,719) |
1,320,418 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2012-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,524,560 |
3,691,228 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2012-05-16 |
4 |
B |
$6.25 |
$9,375 |
D/D |
1,500 |
5,192,728 |
3.15 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2012-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500,000 |
5,191,228 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2012-09-10 |
4 |
B |
$2.25 |
$112,500 |
D/D |
50,000 |
7,242,728 |
3.23 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2012-09-11 |
4 |
B |
$2.25 |
$225,000 |
D/D |
100,000 |
7,342,728 |
3.23 |
- |
|
| TGTX |
TG Therapeutics Inc |
Chairman, Interim CEO and Pres |
• • • |
2012-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
486,743 |
7,829,471 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2013-12-11 |
4 |
B |
$3.43 |
$34,300 |
D/D |
10,000 |
7,839,471 |
3.23 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
Director |
– • – |
2013-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,979,346 |
1,979,346 |
0 |
- |
|
| TGTX |
TG Therapeutics Inc |
See Remarks |
• • • |
2013-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
491,920 |
8,331,391 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
Exec. VC - Strategic Dev. |
• • – |
2014-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,958,692 |
5,938,038 |
0 |
- |
|
126 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
